Expanded Access for ALS Patients: How Compassionate Use Programs Provide Hope Beyond Clinical Trials

For people living with ALS, time is one of the most precious resources. While clinical trials are essential for developing new treatments, not every patient qualifies to participate. Expanded access for ALS patients, sometimes called compassionate use, provides a pathway for individuals to receive investigational therapies outside of traditional clinical trials. Expanded access programs are designed for patients with serious or life-threatening conditions who have limited treatment options. Through these programs, pharmaceutical companies may allow doctors to request access to experimental drugs that are still being studied but have not yet received full regulatory approval. In the United States, these programs operate under oversight from the U.S. Food and Drug Administration (FDA) to ensure patient safety and ethical use. For ALS patients, expanded access can be especially important. Clinical trials often have strict eligibility criteria related to age, disease stage, respiratory function, or previous treatments. As a result, many people who want to try experimental therapies may not qualify. Expanded access programs help bridge this gap by allowing physicians to request investigational treatments on behalf of individual patients or groups of patients. However, expanded access also comes with challenges. Pharmaceutical companies must balance patient demand with limited drug supply, ongoing research requirements, and safety monitoring. Not every investigational therapy is available through compassionate use programs. Despite these limitations, expanded access remains an important part of the ALS treatment landscape. For many patients and families, it represents hope—an opportunity to pursue promising therapies while scientific research continues to advance toward new treatments and potential cures.